Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine if angiotensin-II AT-1 receptor blockade(ARB) may improve insulin sensitivity assessed by the hyperinsulinaemic isoglycaemic glucose clamp, more than CCB therapy at a comparable dose with regards to the blood pressure-lowering effect.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ullevaal University Hospital
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Amlodipine; Angiotensin II; Angiotensinogen; Losartan

Criteria

Inclusion Criteria:

• Essential hypertension with diastolic blood pressure 95-110 mmHg and systolic blood pressure < 180 mmHg

• Previously untreated hypertension or treated with monotherapy (but not with ACE-inhibitors or Angiotensin II-receptor blockers)

• Impaired glucose tolerance or impaired fasting glucose (fasting plasma glucose; 6.1-7.0 mmol/l (110-126 mg/dl)

• Age over 18

• Informed consent

• Any one of these: Microalbuminuria (urin excretion >20 microg/min), dyslipidemia (HDL-cholesterol <0.9 mmol/l(35 mg/dl), Triglycerides > 1.7 mmol/l (150 mg/dl), waist to hip-ratio >0.9 in men and >0.85 in women, BMI >28 kg/m2.

Exclusion Criteria:

• Previous or current use of ACE-inhibitors or Angiotensin II-receptor blockers

• Previous or current antidiabetic medications

• "Brittle" pre-diabetes where the investigator anticipates pharmacological treatment within next 6 months

• Hypertensive patients where the investigator anticipates polytherapy within next 6 months

• Female patient who is pregnant or nursing or planning pregnancy within the duration of the study